SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Pluristem Therapeutics

28 Jan 2015 10:23 AM <--
18 Oct 2006 11:05 AM

Return to Pluristem Therapeutics
 
Pluristem Life Systems, Inc. (OTCBB PLRS): aims to become a leader in stem cell expansion, specializing initially in hematopoietic stem cells, using its unique 3-D technology platform and proprietary PluriX™ bioreactor. Similarly, the Company will further develop its exclusive stromal cell expression libraries, which are expected to boost bone marrow transplants and significantly improve their success rate while maximizing immune system functioning.
Website pluristem.com

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News